Fitness + RecoveryResearch-onlyAnimal / preclinicalUpdated 2026-04-24

Peptide reference file

MGF

Trending #14 in Fitness8.4k searches/moHyped

Mechano growth factor is discussed as an IGF-related splice variant tied to muscle adaptation and tissue-response signaling.

Current readout: animal / preclinical evidence, research-only status, not approved approval state, human evidence is not established here, no linked trial record is attached yet, and 4 linked sources in the seed trail.

PubChem CID 447728 | 2010 PubMed results | 101 trial records | 1 DailyMed label | 0 Drugs@FDA applications

MGF is mostly discussed because people usually look it up as a recovery or muscle-building peptide connected to training stress.

The public claim is straightforward: People usually look it up as a recovery or muscle-building peptide connected to training stress. Mechanistically interesting but still mostly a preclinical performance story.

In plain language, mechano growth factor is discussed as an IGF-related splice variant tied to muscle adaptation and tissue-response signaling.

Animal / preclinicalResearch-only
IGF axisMuscle adaptationRepair signaling

Aliases: Mechano growth factor, IGF-1Ec

SpecimenMGF specimen
FFFFFFFMgMg
Formula
F3Mg-
Mass
81.301
Evidence
Animal / preclinical
Elements
2

Most commonly discussed in relation to IGF axis, Muscle adaptation, Repair signaling.

What MGF is

Mechano growth factor is discussed as an IGF-related splice variant tied to muscle adaptation and tissue-response signaling.

MGF is grouped under Fitness + Recovery on PeptideFactCheck because people usually look it up as a recovery or muscle-building peptide connected to training stress.

The useful starting point is to separate the molecule itself from the internet story around it. People usually look it up as a recovery or muscle-building peptide connected to training stress.

Why people keep looking it up

People usually look it up as a recovery or muscle-building peptide connected to training stress.

Mechano growth factor is discussed as an IGF-related splice variant tied to muscle adaptation and tissue-response signaling.

MGF tends to stay in the conversation because it touches a familiar public theme: igf axis, muscle adaptation, and repair signaling. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Mechanistically interesting but still mostly a preclinical performance story.

Human evidence for broad physique or recovery claims is not well established in the current literature trail.

The strongest support is mechanistic and preclinical, built around IGF pathway biology.

Why this page carries the current tier: Mechanistically interesting but still mostly a preclinical performance story.

The current seed trail for MGF is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

A lot of the certainty online comes from pathway logic rather than direct human outcome data.

No FDA-approved MGF drug product is represented in this seed set.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for MGF. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for MGF is CID 447728. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
447728
Formula
F3Mg-
Molecular weight
81.301
InChIKey
GJOMWUHGUQLOAC-UHFFFAOYSA-K

Matched synonyms include RefChem:1100420, CHEBI:49739, trifluoromagnesate(1-), TRIFLUOROMAGNESATE, MGF, SCHEMBL29386712.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for MGF returns 101 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for MGF returns 2010 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.